About Avalyn Pharma
Revolutionizing respiratory care with every breath
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Boston, Massachusetts
- Company type
- Privately Held
Avalyn is reimagining the future of pulmonary fibrosis treatment, with a pipeline of new inhaled formulations of approved medicines. Unlike currently available oral therapies, our inhaled approach allows us to tackle the underlying pathophysiology of pulmonary fibrosis at its source by safely delivering treatments directly into the lungs – improving tolerability by decreasing systemic exposure and improving efficacy by increasing lung exposure. Our lead candidate, AP01, is an optimized inhaled formulation of pirfenidone, currently being studied for progressive pulmonary fibrosis in the Phase 2b MIST study. In addition, we completed two Phase 1 studies for AP02, an optimized inhaled formulation of nintedanib. At Avalyn, we are driven by our mission to empower lives through breakthrough inhaled therapies for interstitial lung diseases, turning breathlessness into hope.
Company locations
Boston, Massachusetts 02127, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
Business areas
- Biopharma
- Biotechnology
- Medical
- Pharmaceutical
On LinkedIn
- Followers
- 9,553
- People linked to this company
- 62
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
372,500,000 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.